A Phase 3 interventional study of stavudine extended-release, lamivudine, efavirenz in HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 47 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-25.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing stavudine in HIV Infections — none open to participants now, none under way, none of them phase 3. Stavudine · HIV Infections.
Among the 46 studies testing stavudine in HIV Infections, this one is the 6th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2002, is one of 13 in phase 3, and was the 41st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 46 studies testing stavudine in HIV Infections is open now. The open studies under HIV Infections, anywhere →
Stavudine: first FDA approval 1994 (ZERIT), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 15 · Phase 3 13 · Phase 4 4
First in 1995; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 100 across the 39 interventional studies. Of the 42 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 46 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
77 studies in HIV Infections by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 73 finished, 9 (12%) have results posted.
Among the 77 studies in HIV Infections by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 48 interventional ones that give a count, is one of 6 that started in 2002, is one of 20 in phase 3, and was the 47th registered.
Bristol-Myers Squibb’s HIV Infections studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing stavudine in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 77 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that virologically controlled HIV-infected individuals can successfully switch from a standard-of-care regimen dosed twice-daily or more frequently to a simpler once-daily (QD) regimen while maintaining virologic control, as evaluated by the proportion of subjects who continue to have plasma HIV-1 levels \<50 copies/mL after switching to a QD regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: Stavudine · Lamivudine · Efavirenz
Efficacy at week 48
Safety, tolerability and efficacy at weeks (wks) 24 and 48; Effect on lipids at wks 24 and 48; Adherence, quality of life changes, treatment satisfaction and preference at wks 12, 24 and 48
The record gives a start of Sep 2002, a primary completion of Jul 2005 and a completion of Jul 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Stavudine · Lamivudine · Efavirenz